MedTrace Logo

Gabapentin for the Treatment of Neuroleptic-Induced Tremor

NCT00533455 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-09-24

No results posted yet for this study

Summary

We will attempt to establish whether gabapentin as compared with placebo will reduce the severity of tremors caused by the use of antipsychotic medications. Baseline severity of tremor will be measured using both clinical ratings and ratings obtained with an instrument designed to measure tremor, giving more objective evidence of tremor frequency and severity.

Conditions

  • Neuroleptic-Induced Tremor

Interventions

DRUG

Gabapentin

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Minneapolis Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Charles E Dean, MD · Minneapols VA Medical Center

  • Adityanjee Adityanjee, MD · Minneapolis Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533455 on ClinicalTrials.gov